Children now eligible for screening test for bacterium

(HealthDay) -- The U.S. Food and Drug Administration has expanded approval for a breath test that screens for a common ulcer-causing germ, to include children aged 3 years to 17.

The bacterium causes stomach inflammation (gastritis) and ulcers, and increases an infected person's risk of and a certain form of lymphoma. In a news release, the FDA said the BreathTak UBT test, approved for adults in 1996, is now sanctioned for children.

The U.S. Centers for Disease Control and Prevention estimates that more than two-thirds of the world's population is infected with the bacterium, abbreviated H. pylori, but most infected people never have symptoms, the FDA said.

The BreathTek UBT test was newly approved based on results from a multi-location clinical trial involving 176 children, the agency said.

The test is produced by Otsuka America Pharmaceutical, headquartered in Rockville, Md.

More information: To learn more about H. Pylori, visit the CDC.

add to favorites email to friend print save as pdf

Related Stories

Peptic ulcer bacterium alters the body's defense system

Jun 29, 2009

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery may lead to new treatm ...

Preventing gastric cancer with antibiotics

Mar 12, 2010

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the p ...

Recommended for you

No added benefit proven for umeclidinium/vilanterol in COPD

4 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

User comments